From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Other names FKB01MD
Routes of
By mouth
Pharmacokinetic data
Bioavailability 17%[1]
Elimination half-life 4 hours[1]

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.[2] [1] It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.[3]

See also


  1. ^ a b c Fabre-Kramer: FKB01MD
  2. ^ "Drugs in Clinical Development for Major Depressive Disorder". Pharmaceutical Medicine. 27 (1): 35–42. 2013. doi:10.1007/s40290-013-0007-5. ISSN 1178-2595.
  3. ^ "TGBA01AD". AdisInsight.

Retrieved from ""
This content was retrieved from Wikipedia :
This page is based on the copyrighted Wikipedia article "TGBA01AD"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA